PRZOOM - /newswire/ -
London, United Kingdom, 2007/08/06 - New analysis from Frost & Sullivan, European Asthma Therapeutics Markets, finds that the market earned revenues of $4.90 billion in 2005 and estimates this to reach $9.30 billion in 2013.
Currently available drugs for the treatment of asthma do not demonstrate the desired outcome and are capable only of managing the symptoms. This situation, together with the increase in disease morbidity and mortality, is underlining the pressing need for improved asthmatic drugs that cure the disease rather than merely reduce its symptoms. Hence, the market is brimming with opportunities for innovative asthma therapies.
New analysis from Frost & Sullivan (pharma.frost.com), European Asthma Therapeutics Markets, finds that the market earned revenues of $4.90 billion in 2005 and estimates this to reach $9.30 billion in 2013.
If you are interested in a virtual brochure, which provides manufacturers, end users and other industry participants with an overview of the latest analysis of the European Asthma Therapeutics Markets, send an email to Radhika Menon Theodore, Corporate Communications, at rmtheodore[.]frost.com with your full name, company name, title, telephone number, email address, city, state and country. We will send you the information through e-mail upon receipt of the above information.
“Adherence to treatment guidelines prescribed by GINA will determine the prescription volumes for various therapeutic drugs,” notes Frost and Sullivan Research Analyst Sriram V. “Biologics will witness a big boom in the autoimmune and inflammatory diseases arena and in other disease areas that have a significant unmet need.”
At present, nearly 58 per cent of asthmatics continue with emergency visits due to the lack of adherence to these guidelines. The introduction of Xolair has created tremendous opportunity for biologics. Although there is doubt about the potential financial gains from biologics, their presence as therapeutic alternatives will provide the much-needed boost to balance the intensifying dearth of pipeline products.
“For instance, inhaled corticosteroids are the most sought after and accepted gold standard for treatment,” adds Mr. Sriram. “However, prescription trends among physicians do not reflect this acceptance.”
Concerted efforts should be made to harmonise varied treatments for asthma. The development of treatment alternatives for severe asthma requires immediate attention, even while pharmaceutical companies and other participants in the value chain need to lobby effectively to reduce the national economic burden caused by asthma.
European Asthma Therapeutics Markets is part of the Pharmaceutical & Biotechnology Growth Partnership Services, which also includes research in the following: European Diabetes Market and European CNS Therapeutics Markets. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.
About Frost & Sullivan
Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics.